Kamiren

Doxazosin, the active ingredient in Kamiren, is an alpha-1 adrenergic blocker presented as an oral tablet for oral use. It lowers blood pressure in hypertension and relieves urinary symptoms of benign prostatic hyperplasia in adult patients. GNH USA supplies Kamiren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union pharmacopeial standards and is manufactured under GMP conditions. It is distributed through a regulated supply chain ensuring product integrity from manufacturing to end‑user.

Doxazosin is used to manage conditions related to vascular tone and prostate enlargement. Hypertension: Reduces systemic blood pressure by decreasing peripheral vascular resistance, helping to achieve target blood pressure levels and lowering the risk of cardiovascular complications. Benign prostatic hyperplasia: Improves urinary flow and reduces bladder outlet obstruction symptoms such as nocturia, hesitancy, and incomplete emptying, thereby enhancing quality of life in men with enlarged prostate. Resistant hypertension: Used as part of combination therapy to achieve blood pressure control when first‑line agents are insufficient.

Doxazosin may cause a range of adverse reactions, which are categorized by frequency and severity, and should be monitored. Common Side Effects: - Dizziness: Light‑headedness or vertigo that may occur shortly after the dose, particularly when changing posture. - Headache: Mild to moderate throbbing headache, often transient and may improve with continued therapy. - Fatigue: Generalized tiredness or lack of energy that can affect daily activities. Serious or Rare Side Effects: - Orthostatic hypotension: Sudden and significant drop in blood pressure upon standing, leading to possible falls. - Syncope: Episodes of fainting that may be preceded by dizziness or palpitations. - Liver injury: Rare cases of elevated liver enzymes or hepatitis requiring medical evaluation.

When prescribing Doxazosin, clinicians should consider several precautionary measures to ensure patient safety. - Blood pressure monitoring: Check supine and standing pressures after initiation and dose changes. - Cardiovascular status: Evaluate for existing heart failure or coronary artery disease before use. - Renal function: Adjust therapy in patients with severe renal impairment. - Concomitant antihypertensives: Use caution when combined with other blood‑pressure‑lowering agents to avoid excessive hypotension. - Pregnancy and lactation: Avoid use unless benefits clearly outweigh potential risks, as safety data are limited. - Store at ambient temperature: Keep tablets below 25 °C in the original container, protected from moisture and light.

Doxazosin can interact with other medicines, altering its efficacy or increasing adverse effects. Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil): Concomitant use may cause an additive vasodilatory effect leading to marked hypotension. - Potassium‑sparing diuretics (e.g., spironolactone, amiloride): Combined therapy can increase the risk of hyperkalemia and excessive blood‑pressure reduction. Moderate Interactions (Monitor Closely): - Other antihypertensive agents: Adding Doxazosin to ACE inhibitors, ARBs, beta‑blockers, or calcium‑channel blockers may require dose titration to avoid overly low blood pressure. - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): May raise Doxazosin plasma concentrations, warranting closer blood pressure monitoring. - NSAIDs (e.g., ibuprofen, naproxen): May blunt the antihypertensive effect of Doxazosin, possibly necessitating dosage adjustment.